Syros to Join May 2024 Investor Conferences

Syros Pharmaceuticals, a biopharmaceutical company listed on NASDAQ under the ticker SYRS, is dedicated to establishing new standards of care for the frontline treatment of hematologic malignancies. The company has announced its participation in two forthcoming investor conferences where its management will engage in fireside chats.

The first event is the JMP Securities 2024 Life Sciences Conference, scheduled for Tuesday, May 14. Syros' presentation is set for 11:00 a.m. ET at the New York Hilton Midtown, situated at 1335 Sixth Avenue in New York City.

The second event on Syros' agenda is TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, which will take place on Wednesday, May 29. This presentation will be held virtually at 1:00 p.m. ET.

For those unable to attend in person, both presentations will be accessible via webcast. Interested parties can find the live webcasts and archived recordings of each presentation on the Investors & Media section of the Syros website. The archived replays will be available for approximately 30 days following each event.

Syros Pharmaceuticals focuses its efforts on the development of tamibarotene, an oral selective retinoic acid receptor alpha (RARα) agonist. This treatment is specifically designed for frontline patients suffering from higher-risk myelodysplastic syndrome and acute myeloid leukemia who exhibit RARA gene overexpression. The company is driven by its mission to serve patients with hematologic malignancies, addressing conditions that have been challenging for other targeted therapies.

By leveraging its expertise and dedication, Syros aims to bring innovative solutions to the market, striving to improve the lives of patients with blood disorders. The company's commitment is evident in its ongoing efforts to research and develop groundbreaking treatments that offer new hope to those affected by these serious conditions.